China Resources Pharmaceutical Group Ltd banner
C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.77 HKD -1.2% Market Closed
Market Cap: HK$36.3B

EV/EBITDA

0.9
Current
2%
Cheaper
vs 3-y average of 0.9

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
0.9
=
Enterprise Value
HK$14.5B
/
EBITDA
HK$17.4B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
0.9
=
Enterprise Value
HK$14.5B
/
EBITDA
HK$17.4B

Valuation Scenarios

China Resources Pharmaceutical Group Ltd is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (0.9), the stock would be worth HK$5.89 (2% upside from current price).

Statistics
Positive Scenarios
3/3
Maximum Downside
No Downside Scenarios
Maximum Upside
+931%
Average Upside
608%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 0.9 HK$5.77
0%
3-Year Average 0.9 HK$5.89
+2%
Industry Average 9.2 HK$57.15
+891%
Country Average 9.6 HK$59.51
+931%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
HK$14.5B
/
Jan 2026
HK$17.4B
=
0.9
Current
HK$14.5B
/
Dec 2026
HK$20.2B
=
0.7
Forward
HK$14.5B
/
Dec 2027
HK$21B
=
0.7
Forward
HK$14.5B
/
Dec 2028
HK$19.8B
=
0.7
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
HK
China Resources Pharmaceutical Group Ltd
HKEX:3320
36.7B HKD 0.9 8.7
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 27.4 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 16.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.9 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 15.6 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 12.1 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 9.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8.4 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 7.6 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 7.2 16.8

Market Distribution

Lower than 94% of companies in Hong Kong
Percentile
6th
Based on 1 325 companies
6th percentile
0.9
Low
0 — 4.8
Typical Range
4.8 — 14.9
High
14.9 —
Distribution Statistics
Hong Kong
Min 0
30th Percentile 4.8
Median 9.6
70th Percentile 14.9
Max 9 749.3

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
36.3B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
15.9 HKD
Undervaluation 64%
Intrinsic Value
Price HK$5.77
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett